Search company, investor...

Health Value Creation

Submit Your Analyst Briefing


Series A | Alive

Total Raised


Last Raised

$2.37M | 5 yrs ago

About Health Value Creation

Health Value Creation focuses on surgical devices for laparoscopic and bowel surgery. The first device is a diagnostic tool for preventing anastomotic leakages after bowel surgery. By predicting the quality of the anastomosis during surgery, post-operative complications may be dramatically reduced, saving lives and lowering healthcare costs.

Headquarters Location

Oxfordlaan 70

Maastricht, 6229,


+31 433881759

Missing: Health Value Creation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Health Value Creation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Health Value Creation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Health Value Creation is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,493 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Latest Health Value Creation News

Health Value Creation raises €2 million for Innovative Surgical Devices

Aug 16, 2018

Chemelot Ventures Health Value Creation raises €2 million for Innovative Surgical Devices For Dutch please scroll down. Health Value Creation BV, an innovative startup focusing on surgical devices for laparoscopic and bowel surgery, has raised €2 million in funding. The Series A round was led by Chemelot Ventures, assisted by co-investors Limburg Business Development Fund (LBDF) and existing shareholder Inkef Capital. The company will use the funding to obtain regulatory approval for two devices. Located at the Brightlands Maastricht Health Campus, Health Value Creation, recently completed design and clinical research studies for its two innovative devices with very promising results. The first device is a unique diagnostic tool for preventing anastomotic leakages after bowel surgery. By predicting the quality of the anastomosis during surgery, post-operative complications may be dramatically reduced, saving lives and lowering healthcare costs. The second device is a trocar closure device for faster, safer and more secure suturing. It has proven to be effective in optimally closing trocar wounds after laparoscopic surgery and reduces the chances of wound herniation. The company intends to use the results of the clinical study to apply for market approval in Europe (CE mark) as well as the U.S. (510K). “We are very pleased with our new investors Chemelot Ventures and LBDF, and the resources and network they have at their disposal. Thanks to its direct access to clinicians and other medical professionals, being based at the Brightlands Maastricht Health Campus, is of tremendous value in the next phase of growing Health Value Creation,” says John Marugg, CEO of Health Value Creation. “Each year, over 1,500,000 bowel surgeries are performed in Europe and the U.S. It is estimated that up to 150,000, or one in ten patients, will suffer from an anastomotic leakage, with an 8% mortality rate (12,000 individuals annually) and €1.8 billion in additional healthcare costs globally. We aim to help prevent these complications, thus saving lives and greatly reducing the associated costs,” says Dr. A. Veenhof, founder and CSO of Health Value Creation. “The first human trials have already been very encouraging. Further optimization and validation is expected to result in rapid market approval and acceptance”, according to Marcel Kloosterman, Director of Chemelot Ventures. “This investment is not only beneficial for the company but also for the economic development of Limburg as it will create jobs,” says Martin Schreurs/investment manager at LBDF. Note for the press: for more information please contact Dr. John Marugg, Chief Executive Officer, Health Value Creation. Phone number: +31 (0)6 53 93 37 25 Health Value Creation brengt €2 miljoen bijeen voor innovatieve chirurgische apparatuur Health Value Creation BV, een innovatieve startup die zich richt op chirurgische apparatuur voor laparoscopische ingrepen en darmchirurgie, heeft €2 miljoen aan financiering bijeen weten te brengen. De Serie A-financieringsronde werd aangevoerd door Chemelot Ventures, hierbij geassisteerd door mede-investeerders Limburg Business Development Fund (LBDF) en de reeds bestaande aandeelhouder Inkef Capital. Het bedrijf zal deze financiering gebruiken om overheidsgoedkeuringen voor twee instrumenten te verkrijgen. Health Value Creation, gevestigd op de Brightlands Maastricht Health Campus, heeft onlangs design- en klinische researchonderzoeken afgerond voor twee innovatieve instrumenten. De resultaten hiervan zijn zeer veelbelovend. Het eerste instrument is een uniek diagnostisch hulpmiddel voor de preventie van anastomoselekkages na darmoperaties. Door de kwaliteit van de anastomose tijdens de operatie te voorspellen, kunnen postoperatieve complicaties drastisch worden verminderd. Zo worden levens gered en de kosten voor gezondheidszorg omlaag gebracht. Het tweede instrument is een sluitingsinstrument voor een snellere, veiligere en betere wondhechting bij trocartgebruik. Dit instrument heeft reeds aangetoond te kunnen zorgen voor optimale sluiting van trocartwonden na laparoscopische ingrepen en vermindert de kans op wondbreuken. Het bedrijf is van plan om de resultaten van het klinische onderzoek te gebruiken om marktgoedkeuring aan te vragen in Europa (CE-markering) en in de VS (510K). “We zijn erg blij met onze nieuwe investeerders Chemelot Ventures en LBDF, en met de middelen en netwerken waarover zij kunnen beschikken. De vestiging van ons bedrijf op de Brightlands Maastricht Health Campus, en de rechtstreekse toegang tot clinici en andere medische experts die dit biedt, is van zeer grote waarde in de volgende fase van de groei van Health Value Creation,” zo vertelt John Marugg, CEO van Health Value Creation. “Jaarlijks worden er anderhalf miljoen darmoperaties uitgevoerd in Europa en de VS. Naar schatting hebben ongeveer 150.000 hiervan, ofwel een op de tien patiënten, last van anastomoselekkage, met wereldwijd een overlijdenspercentage van 8% (12.000 mensen per jaar) en €1,8 miljard aan extra kosten voor de gezondheidszorg. Ons streven is het voorkomen van deze complicaties, zodat op die manier levens kunnen worden gered en de aanverwante kosten sterk kunnen worden gereduceerd,” zegt Dr. A. Veenhof, oprichter en CSO van Health Value Creation. “De eerste tests met menselijke patiënten zien er veelbelovend uit. Naar verwachting zal verdere optimalisatie en validatie leiden tot een snelle marktgoedkeuring en acceptatie”, aldus Marcel Kloosterman, directeur van Chemelot Ventures. “Deze investering is niet alleen voordelig voor het bedrijf, maar de banen die hierdoor worden gecreëerd dragen ook bij aan de economische ontwikkeling in Limburg,” zo verklaart Martin Schreurs, investeringsmanager bij LBDF. Noot voor de pers: Voor verdere informatie kunt u terecht bij Dr. John Marugg, Chief Executive Officer Health Value Creation. Telefoon: +31 (0)6 53 93 37 25. E-mail:

Health Value Creation Frequently Asked Questions (FAQ)

  • Where is Health Value Creation's headquarters?

    Health Value Creation's headquarters is located at Oxfordlaan 70, Maastricht.

  • What is Health Value Creation's latest funding round?

    Health Value Creation's latest funding round is Series A.

  • How much did Health Value Creation raise?

    Health Value Creation raised a total of $2.37M.

  • Who are the investors of Health Value Creation?

    Investors of Health Value Creation include INKEF Capital, Brightlands Venture Partners and Limburg Business Development Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.